.
Dupilumab, a fully human monoclonal antibody, blocks the receptors for interleukins 4/13, key and central drivers of type 2 inflammation. Clinical trials demonstrated the safety and efficacy of dupilumab in patients with moderate-to-severe asthma. Here, we aim to describe baseline characteristics of patients initiating dupilumab for asthma, to characterize its safety and effectiveness in real-world clinical practice. REVEAL (pRospEctiVe charactErization of asthma patients treated with dupilumAb in a reaL-world setting; NCT04550962) is a longitudinal, prospective, 3-year observational study of patients aged ≥12 years prescribed dupilumab for asthma in Latin America, the Middle East, Russian Federation, and Singapore per country-specific prescribing information. Of 376 patients enrolled, 374 were included in the effectiveness analysis set. Most were female (62.6
Digital perioperative programs offer promising solutions to overcome organizational constraints of traditional prehabilitation, potentially improving recovery while reducing healthcare burden and costs. We aimed to assess the impact of adding a surgery-specific module to an optimized digital perioperative program on improving functional outcomes after radical prostatectomy (RP). This was a multicentre, prospective, comparative, non-randomized trial including consecutive robot-assisted RP. Intervention was the implementation of the Betty (Better Surgery) coaching program combined with the activation of a RP-specific pre- and rehabilitation module. The primary endpoint was continence recovery, defined as “0 or 1 safety pad per day” at 6 weeks after surgery. Secondary endpoints were mid-term continence, need for postoperative physiotherapy, erectile function, complications, and readmissions. A total of 177 and 156 RP cases were included in the control and experimental groups. Baseline and pathological variables were statistically comparable between groups. The mean patient age and PSA were 65.3 years and 11 ng/ml, respectively. At 6 weeks after RP, 83.3
Background: The standard surgical management of Kummell's disease consists of kyphosis reduction and augmentation of the affected vertebrae. This can be achieved by vertebral augmentation alone or vertebral augmentation in addition to instrumentation. This meta-analysis was conducted to compare vertebral augmentation alone or vertebral augmentation in addition to instrumentation in terms of post-operative complications, improvement in radiographic parameters, and patient-reported outcomes in Kummell's disease. Methods: PubMed, Cochrane, and Google Scholar (page 1-20) were searched till August 2024. The studied outcomes were the complications, intra-operative bleeding, operating time, anterior vertebral height, kyphotic Cobb angle and the improvement in back pain with the Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI). Results: Four studies were included in this meta-analysis. Operative time and Intra-operative bleeding were significantly higher in vertebral augmentation with fixation (p < 0.00001). No difference was seen in the remaining outcomes between both surgeries. Conclusion: Vertebral augmentation, either in combination with fixation or as a standalone procedure, has demonstrated remarkable efficacy in treating Kummell's disease. Both approaches have shown comparable rates of complications, achieved similar radiographic outcomes, and effectively reduced post-operative pain. However, it is important to note that vertebral augmentation combined with instrumentation and fixation does come with some drawbacks, as it requires more operative time and is associated with higher blood loss.
INTRODUCTION:RVIII-SingleChain is a B-domain-truncated factor VIII construct with a covalent bond between the factor VIII heavy and light chains. AIM:We report on the efficacy and safety of rVIII-SingleChain in subjects with severe haemophilia A undergoing surgery. METHODS:Surgery, elective or emergent, was defined as all procedures requiring general, spinal, or regional anaesthesia. rVIII-SingleChain was administered as a bolus or continuous infusion during the perioperative period, dosed individually at the discretion of the investigator based upon the type of surgery and clinical status of the patient. The investigator rated haemostatic efficacy on a 4-point scale (excellent, good, moderate or poor/no response), where treatment success was defined as excellent or good. RESULTS:Overall, 36 subjects underwent 48 surgeries: 41 surgeries in 30 adult/adolescent (mean age 34 [range 12-64] years) and 7 in 6 paediatric subjects (mean age 8 [5-11] years). rVIII-SingleChain was administered during 24 orthopaedic and 17 non-orthopaedic surgeries in adults/adolescents and 7 non-orthopaedic surgeries in paediatrics. Haemostatic efficacy was rated as excellent (n = 36, 88%) or good (n = 5, 12%) in adult/adolescent surgeries and as excellent (n = 7, 100%) in paediatric surgeries. In adults/adolescents, mean (standard deviation [SD]) blood loss was lower than predicted (68.6 [99.9] mL vs. 196.7 [292.8] mL); values were comparable in paediatric subjects (2.1 [2.7] mL vs. 2.9 [2.7] mL). No serious or related adverse events (AEs) were reported during the perioperative period. CONCLUSION:Perioperative administration of rVIII-SingleChain effectively achieves and maintains haemostatic control in adult/adolescent and paediatric subjects with haemophilia A undergoing surgery.
